Literature DB >> 28651370

Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program.

Catherine Kim1, Dana Dabelea2, Rita R Kalyani3, Costas A Christophi4, George A Bray5, Xavier Pi-Sunyer6, Christine H Darwin7, Swaytha Yalamanchi3, Elizabeth Barrett-Connor8, Sherita Hill Golden3, Edward J Boyko9.   

Abstract

Context: The degree to which changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) relate to corresponding changes in plasma sex steroids is not known. Objective: We examined whether changes in VAT and SAT areas assessed by computed tomography were associated with changes in sex hormones [dehydroepiandrosterone sulfate (DHEAS), testosterone, estradiol, estrone, and sex hormone binding globulin (SHBG)] among Diabetes Prevention Program participants. Design: Secondary analysis of a randomized trial. Participants: Overweight and glucose-intolerant men (n = 246) and women (n = 309). Interventions: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise or metformin administered 850 mg twice a day or placebo. Main Outcome Measures: Associations between changes in VAT, SAT, and sex hormone changes over 1 year.
Results: Among men, reductions in VAT and SAT were both independently associated with significant increases in total testosterone and SHBG in fully adjusted models. Among women, reductions in VAT and SAT were both independently associated with increases in SHBG and associations with estrone differed by menopausal status. Associations were similar by race/ethnicity and by randomization arm. No significant associations were observed between change in fat depot with change in estradiol or DHEAS. Conclusions: Among overweight adults with impaired glucose intolerance, reductions in either VAT and SAT were associated with increased total testosterone in men and higher SHBG in men and women. Weight loss may affect sex hormone profiles via reductions in visceral and subcutaneous fat.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28651370      PMCID: PMC5587076          DOI: 10.1210/jc.2017-00967

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2.

Authors:  M N Dieudonne; R Pecquery; M C Leneveu; Y Giudicelli
Journal:  Endocrinology       Date:  2000-02       Impact factor: 4.736

2.  Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women's Health Across the Nation.

Authors:  Rachel P Wildman; Ping G Tepper; Sybil Crawford; Joel S Finkelstein; Kim Sutton-Tyrrell; Rebecca C Thurston; Nanette Santoro; Barbara Sternfeld; Gail A Greendale
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

3.  Gonadal steroids and body composition, strength, and sexual function in men.

Authors:  Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

4.  Association between sex hormones and adiposity: qualitative differences in women and men in the multi-ethnic study of atherosclerosis.

Authors:  Morgana L Mongraw-Chaffin; Cheryl A M Anderson; Matthew A Allison; Pamela Ouyang; Moyses Szklo; Dhananjay Vaidya; Mark Woodward; Sherita Hill Golden
Journal:  J Clin Endocrinol Metab       Date:  2015-01-30       Impact factor: 5.958

5.  The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study.

Authors:  Beth A Mohr; Shalender Bhasin; Carol L Link; Amy B O'Donnell; John B McKinlay
Journal:  Eur J Endocrinol       Date:  2006-09       Impact factor: 6.664

Review 6.  Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.

Authors:  Tarig Elraiyah; Mohamad Bassam Sonbol; Zhen Wang; Tagwa Khairalseed; Noor Asi; Chaitanya Undavalli; Mohammad Nabhan; Osama Altayar; Larry Prokop; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2014-10       Impact factor: 5.958

7.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.

Authors:  William Rosner; Richard J Auchus; Ricardo Azziz; Patrick M Sluss; Hershel Raff
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

8.  Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.

Authors:  Andreas Peter; Konstantinos Kantartzis; Jürgen Machann; Fritz Schick; Harald Staiger; Fausto Machicao; Erwin Schleicher; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2010-09-14       Impact factor: 9.461

9.  Testosterone and depressive symptoms among men in the Diabetes Prevention Program.

Authors:  Catherine Kim; Elizabeth Barrett-Connor; Vanita R Aroda; Kieren J Mather; Costas A Christophi; Edward S Horton; Xavier Pi-Sunyer; George A Bray; Fernand Labrie; Sherita Hill Golden
Journal:  Psychoneuroendocrinology       Date:  2016-06-15       Impact factor: 4.905

10.  Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat.

Authors:  Elaine C Tsai; Alvin M Matsumoto; Wilfred Y Fujimoto; Edward J Boyko
Journal:  Diabetes Care       Date:  2004-04       Impact factor: 19.112

View more
  15 in total

1.  Sex Hormones and Measures of Kidney Function in the Diabetes Prevention Program Outcomes Study.

Authors:  Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

2.  Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Edward Giovannucci; Kathryn M Wilson; Thor Aspelund; Laufey Tryggvadottir; Lara G Sigurdardottir; Tamara B Harris; Lenore J Launer; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Cancer       Date:  2019-06-10       Impact factor: 6.860

3.  Circulating Biomarker Score for Visceral Fat and Risks of Incident Colorectal and Postmenopausal Breast Cancer: The Multiethnic Cohort Adiposity Phenotype Study.

Authors:  Loïc Le Marchand; Lynne R Wilkens; Ann M Castelfranco; Kristine R Monroe; Bruce S Kristal; Iona Cheng; Gertraud Maskarinec; Meredith A Hullar; Johanna W Lampe; John A Shepherd; Adrian Franke; Thomas Ernst; Unhee Lim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-04       Impact factor: 4.254

4.  Long-term weight loss maintenance, sex steroid hormones, and sex hormone-binding globulin.

Authors:  Catherine Duggan; Jean de Dieu Tapsoba; Frank Stanczyk; Ching-Yun Wang; Karen Foster Schubert; Anne McTiernan
Journal:  Menopause       Date:  2019-04       Impact factor: 2.953

5.  Childhood adiposity and adolescent sex steroids in the Exploring Perinatal Outcomes among Children study.

Authors:  Catherine Kim; Kylie K Harrall; Deborah H Glueck; Daniel Shumer; Dana Dabelea
Journal:  Clin Endocrinol (Oxf)       Date:  2019-07-14       Impact factor: 3.478

Review 6.  Erectile dysfunction and diabetes: A melting pot of circumstances and treatments.

Authors:  Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli
Journal:  Diabetes Metab Res Rev       Date:  2021-09-21       Impact factor: 8.128

7.  Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer.

Authors:  Melinda S Yates; Adriana M Coletta; Qian Zhang; Rosemarie E Schmandt; Meena Medepalli; Denise Nebgen; Beth Soletsky; Andrea Milbourne; Erma Levy; Bryan Fellman; Diana Urbauer; Ying Yuan; Russell R Broaddus; Karen Basen-Engquist; Karen Lu
Journal:  Cancer Prev Res (Phila)       Date:  2018-05-01

Review 8.  The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments.

Authors:  Varun S Venkatesh; Mathis Grossmann; Jeffrey D Zajac; Rachel A Davey
Journal:  Obes Rev       Date:  2022-01-27       Impact factor: 10.867

Review 9.  Sex and Gender Differences in Prevention of Type 2 Diabetes.

Authors:  Jürgen Harreiter; Alexandra Kautzky-Willer
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-04       Impact factor: 5.555

10.  Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Yuan Chi; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.